PMID- 29665986
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20190320
IS  - 1879-3061 (Electronic)
IS  - 1043-2760 (Linking)
VI  - 29
IP  - 6
DP  - 2018 Jun
TI  - Prevention and Treatment of Type 2 Diabetes: A Pathophysiological-Based Approach.
PG  - 370-379
LID - S1043-2760(18)30059-6 [pii]
LID - 10.1016/j.tem.2018.03.014 [doi]
AB  - Prediabetes affects approximately 40% of American adults. Randomized trials 
      report that a proportion of individuals with prediabetes develop diabetes despite 
      caloric restriction, physical activity, and/or when treated with metformin, the 
      first-line medication for patients with type 2 diabetes mellitus (T2DM). 
      Currently, there are no valid predictors of the effectiveness of these measures 
      in determining who will and who will not progress to the T2DM state. Few studies 
      have examined the clinical and phenotypic predictors of better and worse glycemic 
      response to lifestyle interventions and metformin in prediabetes and diabetes. 
      Further studies incorporating 'omic' approaches to discover novel markers of 
      phenotypes and treatment effectiveness may pave the way to personalizing the 
      treatment of prediabetes and diabetes.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Samocha-Bonet, Dorit
AU  - Samocha-Bonet D
AD  - Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, 
      NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, 
      University of New South Wales, Sydney, NSW 2010, Australia. Electronic address: 
      d.samochabonet@garvan.org.au.
FAU - Debs, Sophie
AU  - Debs S
AD  - Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, 
      NSW 2010, Australia.
FAU - Greenfield, Jerry R
AU  - Greenfield JR
AD  - Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, 
      NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, 
      University of New South Wales, Sydney, NSW 2010, Australia; Department of 
      Endocrinology and Diabetes Services, St Vincent's Hospital, Sydney, NSW 2010, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180414
PL  - United States
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/genetics/microbiology/*prevention & 
      control
MH  - Gastrointestinal Microbiome/drug effects
MH  - Genomics
MH  - Humans
MH  - Metformin/*therapeutic use
MH  - Prediabetic State/drug therapy/genetics/microbiology/prevention & control
OTO - NOTNLM
OT  - genomics
OT  - gut microbiomics
OT  - metabolomics
OT  - metformin
OT  - personalized management
OT  - prediabetes
EDAT- 2018/04/19 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/04/19 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2018/03/16 00:00 [revised]
PHST- 2018/03/16 00:00 [accepted]
PHST- 2018/04/19 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2018/04/19 06:00 [entrez]
AID - S1043-2760(18)30059-6 [pii]
AID - 10.1016/j.tem.2018.03.014 [doi]
PST - ppublish
SO  - Trends Endocrinol Metab. 2018 Jun;29(6):370-379. doi: 10.1016/j.tem.2018.03.014. 
      Epub 2018 Apr 14.